Rocco Verducci

What is GSK Thinking With Its Latest NDA?

Eben,

It might be prudent to examine the total body of clinical work before rendering a negative opinion on Promacta or GSK. The FDA's outside advisory board of learned clinicians opined a positive outlook about Promacta with respect to ITP. Historically, the FDA follows the guidance of the advisory board.

Sincerely,